Dr. Bulent Ozpolat MD has completed his PhD in Immunology at The University of Texas –Houston, MD Anderson Cancer Center and postdoctoral studies focusing on cancer biology, and nanotechnology the same center. He is current servings as an Associate professor at the Department of Experimental Therapeutics at MD Anderson cancer Center. His research focuses on identification of novel molecular targets (genes, microRNA, proteins) 2) Development of targeted-therapies for these pathways utilizing nanotechnology by delivery of therapeutic peptides, small molecule inhibitors siRNA and microRNA. Dr. Ozpolat a member of Center for Targeted Therapy, Genetics and Genomics Center, Center for Targeted Therapy, Texas-Center of Cancer Nanomedicine, and Non-Coding siRNA Center at MDACC. He serve as a reviewer for US-Congressional directed Medical research and Department of Defense (DOD)-Breast cancer and Immunology study sections, Italian health Ministry, British Cancer Foundation grants and several journals as an Editorial Board member and holds several patents published more than 50 papers, 13 reviews and 12 book chapters. His research is supported by NIH, DOD, Susan Komen, and grants from Texas Stae (CPRIT), intuitional/internally funded grants/projects.